Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Video Capsule Endoscopy to Investigate the Safety and Tolerability of Lumiracoxib in the Small Bowel

This study has been completed.
Information provided by:
Novartis Identifier:
First received: July 5, 2006
Last updated: December 12, 2007
Last verified: December 2007
This study is designed to investigate the potential differences in GI safety and tolerability in the small bowel between lumiracoxib, conventional non-selective NSAID (naproxen) with a proton pump inhibitor (omeprazole), or placebo.

Condition Intervention Phase
Healthy Volunteers
Drug: Lumiracoxib
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A 16-Day, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Trial Comparing Lumiracoxib 100mg o.d. With Naproxen 500 mg b.i.d. Plus Omeprazole 20mg o.d. and Placebo in Healthy Volunteers to Investigate on the Safety and Tolerability of Lumiracoxib in the Small Bowel.

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Percentage of subjects with one or more small bowel mucosal breaks (with or without hemorrhage) detected by video capsule endoscopy

Secondary Outcome Measures:
  • Total number of small bowel mucosal breaks (with or without hemorrhage) detected by video capsule endoscopy
  • Percentage of subjects with one or more small bowel lesion detected by video capsule endoscopy
  • Total number of small bowel lesions detected by video capsule endoscopy
  • Value of small bowel inflammation (as measured by calprotectin test)
  • Value of lower GI permeability for lumiracoxib (as measured by differential urinary excretion of sugars)

Estimated Enrollment: 150
Study Start Date: May 2006

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Healthy male or female subjects

Exclusion Criteria:

  • Evidence of cardiovascular, hepatic, gastrointestinal or renal disorders
  • Hereditary problems of galactose intolerance, a severe lactase deficiency or glucose-galactose malabsorption syndrome
  • Smokers

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00350155

Wiesbaden, Germany
United Kingdom
Nottingham, United Kingdom
Sponsors and Collaborators
Study Chair: Novartis Pharma AG Novartis Pharmaceuticals
  More Information Identifier: NCT00350155     History of Changes
Other Study ID Numbers: CCOX189A2425
Study First Received: July 5, 2006
Last Updated: December 12, 2007

Keywords provided by Novartis:
Video capsule endoscopy, healthy volunteers, naproxen, omeprazole, lumiracoxib, small bowel

Additional relevant MeSH terms:
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Gout Suppressants processed this record on April 25, 2017